Long-term outcomes of high-dose conbercept treatment for myopic cho-roidal neovascularisation and idiopathic choroidal neovascularisation.

The BCVA of group A improved from 0.31 ±0.16 logMAR at baseline to 0.12 ± 0.03logMAR at the final follow-up (P < 0.001), while in group B the corresponding im-provement was from 0.33 ± 0.16logMAR at baseline to 0.12 ± 0.03logMAR at the final fol-low-up (P < 0.001). Visual acuity improved in 17 subjects in group A and 15 in group B, while it remained stable in 3 subjects each in groups A and B. CRT decreased from 311.83 ± 30.95 μm in group A and 351.17 ± 37.09 μm in group B pre-operation to 229.56 ± 5.75 μm and 227.67 ± 4.98 μm at 24 months follow-up, respectively (P < 0.001 in groups A and B). Metamorphopsia was improved in subjects in groups A and B. CNV had disappeared in the two groups at the last postoperative visit. The BCVA, CRT, and CNV area were no statisti-cal differences between the two groups at 6, 12, and 24 months follow-up (p > 0.05). Con-clusion: Intravitreal injection of conbercept (1 mg 2+PRN scheme) is effective for treating patients with mCNV or iCNV, which can improve and stabilize vision as well as dramatical-ly alleviate metamorphopsia.